Showing 3741-3750 of 7238 results for "".
- Intravenous Ertapenem Shows Improvement in Hidradenitis Suppurativahttps://practicaldermatology.com/news/intravenous-ertapenem-for-hidradenitis-suppurativa-efficacy-and-patient-satisfaction/2462245/Results from a new analysis indicated that intravenous ertapenem was associated with improvements in markers of hidradenitis suppurativa (HS) and was linked with increased patient satisfaction. The retrospective analysis included medical records of 98 patients with HS who
- Highlights from Maui Derm 2024https://practicaldermatology.com/news/highlights-from-maui-derm-2024/2462227/The Maui Derm 2024 Conference showcased a wide array of advancements in dermatology, from innovative treatments to exciting new therapies, to business opportunities to the latest research. Here, Practical Dermatology recap
- BE HEARD Analysis: Bimekizumab Maintains Treatment Response at 48 Weeks in HShttps://practicaldermatology.com/news/be-heard-analysis-bimekizumab-maintains-treatment-response-at-48-weeks-in-hs/2462220/A pooled analysis of data from the BE HEARD I and BE HEARD II trials presented at Maui Derm 2024 suggested adults with moderate-to-severe hidradenitis suppurativa (HS) treated with bimekizumab (BKZ) saw a sustained clin
- Researchers Identify Factors Limiting New Treatment Decisions for HShttps://practicaldermatology.com/news/factors-affecting-treatment-selection-among-patients-with-hidradenitis-suppurativa/2462211/Researchers seeking to address the gap between evidence-based guidelines and clinical practice in the treatment of hidradenitis suppurativa (HS) have identified several factors influencing patient decision-making. The open-ended, two-center study, conducted through open-ended interviews
- FDA Deems Vaporized Hydrogen Peroxide an Established Method of Sterilizationhttps://practicaldermatology.com/news/fda-deems-vaporized-hydrogen-peroxide-an-established-method-of-sterilization/2462205/The U.S. Food and Drug Administration (FDA) announced that it now considers vaporized hydrogen peroxide (VHP) as an established method of sterilization for medical devices. In what the agency called a recognition of its long-time effectiveness, it revised the final guidance on the
- Melanoma Rates Among Non-Hispanic American Indian/Alaska Natives Vary by Age, Region: Studyhttps://practicaldermatology.com/news/melanoma-rates-among-non-hispanic-american-indianalaska-native-individuals/2462199/A new study in JAMA Dermatology shed light on trends and incidence rates of invasive cutaneous melanoma in non-Hispanic American Indian/Alaska Native individuals. The cross-sectional observational study, focusing on a period from 1999 to 2019, included data drawn from a populati
- Upadacitinib Linked with Improvement for Hand Eczema in Patients with Atopic Dermatitishttps://practicaldermatology.com/news/updacitinib-shows-promise-for-ad-and-hand-eczema-in-trial/2462198/Results from a new study suggest that upadacitinib is efficacious for the treatment of hand eczema (HE) and atopic dermatitis (AD) in patients with AD. The study authors, publishing in Contact Dermatitis, included a total of 38 patients in the observational cohort analysis (32 of
- Seaweed- and Carbonated Water-based Hydrogel Shows Promise for Treatment of Skin Woundshttps://practicaldermatology.com/news/revolutionary-seaweed-and-carbonated-water-based-hydrogel-for-treating-skin-wounds/2462184/Results from a new study suggested promise for a new seaweed- and carbonated water-based hydrogel that aims to prevent the temporary dilation of wound sites. Researchers developed a low-adhe
- Lindus Health and Thirty Madison Complete Enrollment of Personalized Dermatology Care Pilot Studyhttps://practicaldermatology.com/news/lindus-health-and-thirty-madison-complete-enrollment-of-personalized-dermatology-care-pilot-study/2462182/Clinical trial company Lindus Health and Thirty Madison, a US-based family of specialized healthcare brands, announced the completion of enrolment of a pilot study to assess the effectiveness of their personalized dermatology telemedicine platform Facet. The novel teleh
- Scinai Announces Promising Results in a Psoriatic Human Skin Modelhttps://practicaldermatology.com/news/scinai-announces-promising-results-in-a-psoriatic-human-skin-model/2462180/Scinai Immunotherapeutics Ltd. announced a successful preclinical trial result for its anti-IL-17 VHH antibody (NanoAb) as a local treatment for moderate plaque psoriasis. The study, designed to evaluate the anti-inflammatory effects of NanoAbs, used proprietary induced human